Pitavastatin plus Ezetemibe

PreclinicalSmall molecule

Pitavastatin plus Ezetemibe is one of 56 small molecule programs targeting Dyslipidemias. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyslipidemiasRecruiting

Cardiovascular DiseaseActive, not recruiting

DyslipidemiasPreclinical

Recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

146 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Primacor

Sanofi

Approved

—2

Cardene

Sun Pharmaceutical Industries, Inc.

Geodon

Giapreza

LLa Jolla Pharmaceutical Company

Midamor

Camzyos

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—7

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Colcrys

1 9

Pelacarsen

Novartis

Phase 3

1 10

Cagrilintide

Novo Nordisk

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Hypertension

NCT07784621

Q2 2027

PreclinicalRecruiting

Dyslipidemias

NCT05705804

Clinical

Trials by Indication[1]

Hypertension2 trials

Neointimal Coverage After Implantation of Biolimus Eluting Stent With Biodegradable Polymer: Optical Coherence Tomographic Assessment According to the Treatment of Dyslipidemia and Hypertension and the Types of Implanted Drug-eluting Stents

Completed·YYonsei University·Phase 4·NCT01502904·120 enrolled

An Open-Label, Multiple-oral Dosing, Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults

Not yet recruiting·HHuons Co., Ltd.·Phase 1·NCT07784621·30 enrolled

Dyslipidemias1 trial

Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

Recruiting·YYonsei University·Preclinical·NCT05705804·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pitavastatin plus Ezetemibe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pitavastatin plus Ezetemibe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pitavastatin plus Ezetemibe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

Pitavastatin plus Ezetemibe

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Hypertension2 trials

Dyslipidemias1 trial

References

Drug Info

Quick Facts

Related News